Denali Therapeutics | 8-K: Denali Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights
Denali Therapeutics | 8-K: Current report
Denali Therapeutics | 8-K: Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
Denali Therapeutics | DEF 14A: Definitive information statements
Denali Therapeutics | DEFA14A: Others
Denali Therapeutics | S-3ASR: Automatic shelf registration statement of securities of well-known seasoned issuers
Denali Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Denali Therapeutics | 8-K: Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
Denali Therapeutics | 8-K: Current report
Denali Therapeutics | 8-K: Current report
Denali Therapeutics | 8-K: Current report
Denali Therapeutics | 8-K: Denali Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights
Denali Therapeutics | 8-K: Current report
Denali Therapeutics | 8-K: Denali Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights
Denali Therapeutics | 8-K: Current report
Denali Therapeutics | 8-K: Current report
Denali Therapeutics | 8-K: Current report
Denali Therapeutics | 8-K: Denali Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights
Denali Therapeutics | DEFA14A: Others
Denali Therapeutics | DEF 14A: Definitive proxy statements
No Data